Target discovery helps identifying drug targets, molecules or molecular interactions at a critical point in a disease-causing pathway that are predicted to being amenable to therapeutic manipulation. The centre aims to link recent advances in genetics, genomics, cell and chemical biology for improved drug target discovery. A more specific focus for refining and validating such targets will provide a better link between traditional "open ended" academic processes to biomedical research and the need of the pharmaceutical industry for accurately defined targets to accelerate drug development.
Dr Kilian Huber has a new paper in press at Nature Methods about a Proteomic Target Discovery method. This method will be established at the TDI with the help of Professor Benedikt Kessler as part of the new Chemoproteomic Profiling Platform.